Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Bright Horizons Family Solutions heads into its November 2 earnings report with analysts trimming targets across the board and short interest quietly rebuilding after a month of sustained accumulation.
The analyst picture has turned notably more cautious this week. UBS lowered its target to $78 from $88 on October 14, keeping a Neutral rating, while Morgan Stanley cut to $64 from $66 the day before, maintaining its Underweight call. BMO Capital also trimmed its Outperform target to $83 from $93 earlier this month. The direction of travel is consistent: every change in recent weeks has been a reduction. The consensus mean target now sits at $86.78, well above the current price of $68.17, but that gap is narrowing as the Street ratchets down expectations. JPMorgan holds the most constructive view at Overweight, though its own target came in from $115 to $105 back in May. With Morgan Stanley's Underweight at $64 sitting close to where the stock trades now, the bear case is not far off market consensus.
Short interest is the other angle worth watching. Bears have rebuilt positions significantly over the past month, with short interest up roughly 27% over 30 days to reach 4.6% of the free float. On Tuesday alone, estimated short shares jumped 5.2% in a single session, suggesting fresh positioning rather than noise. That said, the borrow market offers no squeeze catalyst: availability is extremely loose at over 5,000% of short interest, meaning there are roughly 38 million shares available to borrow against around 2.6 million currently shorted. Cost to borrow is a negligible 0.53%. The picture here is bears adding exposure freely, without any friction from the lending market.
Options positioning has shifted sharply toward calls over the past two weeks, which is the most striking element in the dataset. The put/call ratio dropped to 0.68, nearly a standard deviation below its 20-day average of 3.70. The history shows a dramatic step-change: through mid-September, the PCR ran above 10, and as recently as late September it was holding near 4. That collapse in put demand relative to calls suggests a distinct change in how options traders are framing the stock, moving from heavy downside protection to something closer to neutral-to-bullish positioning, just as the fundamental and analyst backdrop has softened.
On valuation, the stock trades at a PE of roughly 11.9x and an EV/EBITDA near 9.0x, both of which have drifted lower over the past 30 days. The forward earnings growth factor ranks in the 96th percentile, pointing to meaningful expected improvement from current levels, which is where the bull case rests. On the bearish side, the stock is down roughly 35% year-to-date and momentum factors remain deeply negative across every trailing window, reflecting sustained price underperformance against peers. Close correlate LOPE gained 2.1% on the week, ADT added 3.9%, and CSV rose 5.2%, all outpacing BFAM's modest 2.6% weekly recovery.
On the ownership side, BlackRock crossed 13% as of September 30, a significant increase from the 4.3% stake it last reported in early 2025, following a fresh Schedule 13G filing in June. Abrams Bison Investments filed a new 13G in September disclosing a 5.6% stake. No activist 13D is on the register. As the disclosure requires: stakes are as last disclosed around the 5% threshold, and holders dropping below that level may not file again.
The next milestone is the November 2 earnings print. The last quarterly release, on July 30, produced a one-day decline of nearly 10% and a five-day loss of more than 10%, the most punishing earnings reaction in recent history. The combination of target cuts going into that date, short interest at a one-month high, and an options market that has just rotated away from protective puts, sets up an interesting read on where conviction sits heading into the report.
See the live data behind this article on ORTEX.
Open BFAM on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
